Kev piav qhia
Peb 4-amino-5-methyl-2-hydroxypyridine yog ib qho tseem ceeb nruab nrab ntawm cov synthesis ntawm Finerenone, ib tug tshiab non-steroidal xaiv mineralocorticoid receptor antagonist uas muaj peev xwm kho mob plawv thiab raum kab mob.Muaj peev xwm siv tau.Qhov sib xyaw no yog ib qho tseem ceeb hauv kev tsim cov Finerenone, ua rau nws yog ib qho tseem ceeb rau cov tuam txhab tshuaj thiab cov chaw tshawb fawb.
Lub purity thiab zoo ntawm peb 4-amino-5-methyl-2-hydroxypyridine yog unparalleled, ua kom nws haum rau txhua theem ntawm kev tsim tshuaj thiab kev tsim khoom.Nrog rau kev tsom mus rau kev ua tau zoo thiab kev tsim kho tshiab, peb tau ua kom zoo dua peb cov txheej txheem synthesis thiab purification los muab cov khoom ua tau raws li cov qauv nruj ntawm kev lag luam kws tshuaj.
Peb qhov kev cog lus rau kev ua tau zoo txuas mus rau txhua qhov ntawm peb cov haujlwm, los ntawm kev tsim cov khoom siv raw mus rau kev tsim khoom thiab kev faib tawm.Peb ua raws li cov qauv kev nyab xeeb siab tshaj plaws thiab kev ua raws cai kom ntseeg tau tias peb cov neeg siv khoom tau txais cov khoom uas ua tau raws li cov kev cai nruj tshaj plaws.
Xaiv Peb
JDK muaj cov chaw tsim khoom thawj zaug thiab cov cuab yeej tswj kev ua haujlwm zoo, uas ua kom muaj kev ruaj khov ntawm API intermediates.Pab neeg tshaj lij paub tseeb R & D ntawm cov khoom.Tawm tsam ob qho tib si, peb tab tom nrhiav rau CMO & CDMO hauv kev lag luam hauv tsev thiab thoob ntiaj teb.
